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Tear film and ocular surface alterations in
chronic users of antiglaucoma medications
INTRODUCTION
The tear film is a key element for the quality of optical image and
ocular surface health and may be altered by several conditions that disrupt
the homeostasis provided by the neuroimmunoendocrine network(1-3).
Along the last decade, an increase in options for topical glaucoma
therapy raised concern about compliance, persistency, side effects and
complications regarding further treatments(4-6).
The potential damage to the tear film and ocular surface by chronic
and/or addition of glaucoma medications has been suggested by experi-
mental and observational studies. Authors observed higher prevalence of
symptoms, higher expression of inflammatory markers and relative reduc-
tion of some parameters of tear secretion(7-10).
Dry eye and ocular surface damage are the major concerns related to
this chronic, sight-threatening disease since they may have an impact on
all those parameters that affect the success of glaucoma treatment(5,7).
Keywords: Benzalkonium compounds/administration & dosage; Benzalkonium compounds/
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Purpose: Tear film can be altered by chronic medications that may disrupt
the equilibrium responsible for the functioning of  the lacrimal gland and
ocular surface. The purpose of this study was to determine if
antiglaucomatous chronic treatment induced alterations in the tear film
and ocular surface. Methods: After informed consent, 21 patients using
antiglaucomatous eye drops for more than 8 months and 20 age- and sex-
matched volunteers without eye and systemic medications (control
group) were enrolled. The data of ocular discomfort, fluorescein and
lisamine green staining, tear film break-up time and Schirmer test were
collected and compared by Student’s t test. The impression cytology
data were graded and compared by chi-square test. Results: Patients
chronically using antiglaucomatous medications presented with sig-
nificant higher fluorescein staining (p=0.003), lisamine green staining
(p=0.02) and lower TFBUT (p=0.001). The other compared parameters,
including impression cytology were similar between the treated and
control group (p>0.05). Conclusions: The present study shows that the
tear film and the ocular surface are altered in patients under antiglauco-
matous medications. In common, all medications were preserved with
benzalkonium chloride. Efforts to minimize the adverse effects of
chronic use of antiglaucomatous drugs must be addressed.
ABSTRACT
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Since antiglaucomatous drugs are analogs to neurotrans-
mitters, pro-inflammatory or enzymatic mediators they may
interfere in the neuroimmunoendocrine network, disrupting
inflammatory and secretory actions. Moreover, benzalko-
nium chloride as preservative, may induce inflammation or
reduce secretion(11-12).
 Even glaucoma itself has been hypothesized to be related
to dry eye and ocular surface disorder, however no controlled
recent studies compared the status of glaucoma patients un-
der chronic topical medications to control individuals in a
community-based clinical setting(10-13).
The aim of the present study is to evaluate parameters of
ocular surface and tear film of glaucoma patients under
present actual chronic topical therapy compared to control
individuals.
METHODS
Study design
Twenty-one patients followed at the Glaucoma Clinic
participated in the present study. Eye examination was per-
formed and compared to 20 control individuals who accepted
to participate. Signed informed consent was obtained from
all participants.
The study was approved by the University Hospital
Ethics Committee (number 12210/2004) and respected the
Declaration of Helsinki.
Information related to systemic disease and past ocular
history, including glaucoma was recorded from patient chart
and checked during the application of the questionnaire. Pa-
tients with chronic systemic disease, other ocular disease, past
history of ocular surgery or conflicting data were not included.
The control group was selected among age- and gender-
matched individuals without systemic disease and past his-
tory of ocular surgery or topical medication.
Evaluation
Patients and controls were submitted to a routine history
and examination followed by environmental questionnaire
with 10 questions and score range from 0 to 6, from absent to
severe discomfort (Table 1). Tear film and ocular surface
examination consisted of tear film break-up time (TFBUT),
2% fluorescein and 1% lisamine green staining, Schirmer test
(Ophthalmus, São Paulo, Brazil) with topical anesthesia, ac-
cording to previously described guidelines(14).
Impression cytology
The impression cytology was performed collecting con-
junctival cells with a Millipore filter paper (Millipore, Bil-
lerica, MA, USA). Papers were transferred to gelatin-coated
slides, fixed with 70% ethanol, glacial acetic acid and forma-
lin and stained with periodic acid-Schiff (PAS) and hemato-
xilin stain. Epithelium was evaluated in a masked fashion,
according to a classification scheme whereas epithelial cells
were classified into four stages, stage 0 (for normal morpholo-
gy) to stage 3 (squamous metaplasia)(15).
• Stage 0: small, round epithelial cells, large nuclei, abun-
dant goblet cells.
• Stage 1: larger, polygonal cells, smaller nuclei, decrea-
sed number of goblet cells.
• Stage 2: larger, polygonal cells, smaller nuclei, smaller
and rare goblet cells.
• Stage 3: large and polygonal cells, pycnotic or absent
nuclei, absent goblet cells.
Statistical analysis
Data are expressed as means ± SD (standard deviation).
Comparisons were made using Student’s t test for conti-
nuous data (Statview software, Abacus, CA USA) and Fisher
test for categorical data (Graphpad 3.0 software, Prism, San
Diego, CA,USA). The used level of significance was P<0.05.
RESULTS
Both groups presented similar distribution related to age
and sex (p>0.05) (Table 2). The ocular medications in use, at
least during the last 8 months, were listed (Table 3).
The questionnaire of ocular discomfort indicated mean
and standard deviation (SD) levels of 7.9 ± 9.0 for glauco-
matous and 6.9 ± 7.2 for controls (p=0.7), fluorescein stai-
ning of 2.9 ± 3.2 for glaucomatous and 0.6 ± 1.0 for controls
(p=0.003), lisamine green staining of 1.7 ± 1.9 for glaucoma-
tous and 0.4 ± 1.4 for controls (p=0.02), TFBUT of 6.4 ± 5.9
seconds for glaucomatous and 14.1 ± 2.4 seconds for con-
trols (p<0.05), Schirmer test of 14.5 ± 12.0 mm for glauco-
matous and 14.8 ± 9.2 mm for controls (p=0.9).
Impression cytology findings were similar between both
groups. (p>0.05) (Table 4).
DISCUSSION
The negative effects of antiglaucomatous medications on the
ocular surface are known from previous studies and reports(11-13).
Table 1. Items present in the environmental and discomfort ques-
tionnaire. Score ranged from 0 (never) to 6 (all times)
Questions
Light sensitivity
Sand sensation
Burning
Vision fluctuation
Vision improvement with eye drops
Tearing
Eye pain in the evening or in the morning
Blurred vision at driving or reading
Discomfort with wind
Discomfort with air conditioning
71(1)21.pmd 6/3/2008, 10:1619
Arq Bras Oftalmol. 2008;71(1):18-21
20 Tear film and ocular surface alterations in chronic users of antiglaucoma medications
The present study is the first that brings information about
the effects in patients under actual and current therapy in real life
conditions, which means non-selected patient or therapy.
Previous studies have addressed this point but at that time, only
a small number of possible prescriptions were available(12).
Our study identified tear instability and epithelial dama-
ge, but no greater discomfort or reduced tear secretion. Pre-
vious studies have identified lower correlation among dry
eye signs and between signs and symptoms(16).
Moreover, contradictions in this specific subject related
to glaucoma medications were also documented, since the
hypothesis that dry eye syndrome (i.e., less tear secretion)
related to glaucoma itself was brought up, but was not confir-
med by the present study because Schirmer test was similar in
glaucomatous and control individuals(10).
In fact, our patients under chronic antiglaucomatous treatment
have significant signs of epithelial damage, but not of ocular
surface metaplasia. The present hypothesis suggested that pro-
longed treatment would induce changes in the number of goblet
cells and epithelia; however, they may vary with different me-
dications and combinations and duration of treatment(11,14,17).
Due to the heterogeneity of available therapeutic moda-
lities and the variable mechanisms of action, it would be dif-
ficult to determine the causes of ocular surface damage(18).
A possible mechanism already suggested for antiglauco-
matous medications and other chronic ocular medications such
as artificial tears is related to benzalkonium chloride, a preser-
vative that was present in all eye drops used in our study(7,19).
The effects of glaucoma medication or its preservatives may
induce a pro-inflammatory environment in the ocular surface
with affects tissue cicatrization, drug pharmacokinetics, patient
compliance and other factors that ultimately would affect in-
traocular pressure (IOP) control and disease progression(20-21).
The reversibility of signs was previously reported rende-
ring the medication preservative-free eye drops, however the
sequels for the conjunctiva that would interfere in future
clinical and surgical outcomes are unknown(17).
Clinical studies related to dry eye syndrome and ocular
surface damage, like the present study, are difficult in terms
of methodology since there is no agreement between signs and
symptoms, examinations have less sensitivity and the variabi-
lity in the group is broad, due to heterogeneity of factors(22-24).
This observation may indicate that comparisons including
more diagnostic tests and larger samples would identify milder
clinical differences with higher statistical significance.
CONCLUSION
In conclusion, the authors observed that in the current
practice, glaucoma patients under prolonged treatment may
have tear film instability and ocular surface epitheliopathy.
Those events may interfere in treatment compliance and
long-term control of IOP.
RESUMO
Objetivo: O filme lacrimal pode ser alterado por medicações
crônicas, que podem comprometer o equilíbrio responsável
pela função da glândula lacrimal e da superfície ocular. O
objetivo desse estudo foi determinar se o tratamento crônico
com drogas antiglaucomatosas induz alterações no filme la-
crimal e superfície ocular. Métodos: Após o consentimento
informado, 21 pacientes usando drogas antiglaucomatosas
por mais de 8 meses e 20 voluntários com similar distribuição
etária e por sexo, não usuários de medicação ocular ou sistê-
mica (grupo controle) foram incluídos. Os dados do descon-
forto ocular, coloração com fluoresceína e lissamina verde,
tempo de ruptura do filme lacrimal e teste de Schirmer foram
colhidos e analisados pelo teste t de Student. A citologia de
impressão foi avaliada e comparada pelo teste de qui-quadra-
Table 2. Age and sex distribution of patients and controls
Group Glaucomatous Control P
Age (years) 64.1 ± 12.9 63.8 ± 9.2 0.9
Gender 71.4% male 50% male
Table 3. Type and frequency of antiglaucomatous medications in
 use by study group
Medication Frequency Percentage
0.5% timolol maleate qd 38.10%
0.5% timolol maleate BID 14.29%
and 0.2% brimonidine tartrate
0.5% timolol maleate
and 2% pilocarpine hydrochloride BID 9.52%
2% pilocarpine hydrochloride QID 9.52%
0.005% latanaprost qd 4.76%
and 0.2% brimonidine tartrate
0.2% brimonidine tartrate TID 4.76%
0.5% timolol maleate
and 0.2% brimonidine tartrate BID 4.76%
and 0.03% bimatoprost
0.5% timolol maleate BID 4.76%
and 0.2% brimonidine tartrate
and 2% dorzolamide hydrochloride
and 0.005% latanoprost
0.5% timolol maleate BID 4.76%
and 2% dorzolamide hydrochloride
and 2% pilocarpine hydrochloride
and 0.03% bimatoprost
1% brinzolamide hydrochloride TID 4.76%
BID= two times a day; TID= three times a day; qd= once a day;
QID= four times a day
Table 4. Distribution of impression cytology stages among patients
 and controls
Glaucomatous Controls
Altered (stage I or higher) 14 (66.7%) 10 (47.6%)
Non altered (stage 0) 7 (33.3%) 11 (52.4%)
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do. Resultados: Pacientes usando cronicamente medicação
antiglaucomatosa apresentaram significativamente maior co-
loração por fluoresceína (p=0,003), lissamina verde (p=0,02)
e menor TRFL (p=0,001). Os outros parâmetros comparados,
incluindo a citologia de impressão foram similares entre o
grupo tratado e controle (p>0,05). Conclusões: Esse estudo
demonstra que o filme lacrimal e a superfície ocular estão
alterados em usuários de medicação antiglaucomatosa. Essas
medicações apresentam em comum o cloreto de benzalcônio
como conservante. Esforços para minimizar efeitos adversos
do uso crônico de drogas antiglaucomatosas devem ser consi-
derados.
Descritores: Compostos de benzalcônio/administração &
dosagem; Compostos de benzalcônico/efeitos adversos; Ti-
molol/administração & dosagem; Timolol/efeitos adversos;
Disco óptico/efeitos adversos; Glaucoma/quimioterapia; Sín-
drome do olho seco; Indicadores e reagentes
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